Investment
Features
FeesSafety
Academy
More
Pluang+

Compare Novartis AG (NVS) vs Global X Uranium ETF (URA) Price & Performance

Novartis AGTrade
Global X Uranium ETFTrade

Price performance (Past 24H)

Key statistics

Novartis AG vs Global X Uranium ETF — how do they compare? Novartis AG trades at $154.71 (market cap $295.37B), while Global X Uranium ETF trades at $45.28. The key difference: Novartis AG pays a 3.07% dividend while Global X Uranium ETF pays none, and Novartis AG is trading nearer its 52-week high, Global X Uranium ETF nearer its low. Which is the better fit depends on your goals.

NVSURA
Market Cap
$295.37B
Sector
HealthCommodities - Metals/Agriculture
52-Week High
$168.62$61.81
52-Week Low
$119.31$36.45
Enterprise Value
$336.69B
Dividend Yield
3.07%

Aura AI Summary

Signals from Pluang's Aura AI — not financial advice

Novartis AG

Novartis (NVS) trades at $152.41, down 2.79% today, with technical indicators showing neutral momentum near key support at $152. The company reported strong Q2 2026 earnings that beat expectations, driven by oncology drug performance, while maintaining a robust 22.5% net margin and $56.7B in revenue. Recent institutional buying activity and a predominantly Hold analyst consensus reflect cautious optimism amid patent expiration headwinds.

The outlook balances strong fundamentals and pipeline progress against generic competition risks. Investment appeal lies in dividend stability and new drug growth, though Entresto sales decline and U.S. pricing pressures require monitoring. The stock presents a defensive opportunity with moderate upside potential if newer therapies continue outperforming.

Global X Uranium ETF

URA, the Global X Uranium ETF, trades at $45.34, up 2.16% today with a bullish technical signal from moving averages. The ETF benefits from strong nuclear energy tailwinds including $17.5 billion in federal funding and growing AI power demand. Recent index additions like Terra Innovatum and Eagle Nuclear Energy expand the fund's exposure to nuclear infrastructure companies.

The uranium sector faces near-term volatility but long-term structural growth drivers remain intact. Key risks include policy uncertainty and uranium price fluctuations, while opportunities stem from nuclear energy's role in meeting AI power demands and global decarbonization goals.

Returns comparison

Trailing returns across standard periods

Top news

Latest headlines on both assets

About Novartis AG

Novartis develops and manufactures healthcare products through two segments: Innovative Medicines and Sandoz. It generates the vast majority of its revenue from Innovative Medicines segment consisting global business franchises in oncology, ophthalmology, neuroscience, immunology, respiratory, cardio-metabolic, and established medicines. The company sells its products globally, with the United States representing close to one third of total revenue.

Read more on NVS

About Global X Uranium ETF

URA provides broad exposure to the global uranium industry and nuclear energy sector. Unlike pure-play mining funds, it includes companies involved in nuclear component production and infrastructure, with top 2026 holdings such as Cameco, Oklo, and Uranium Energy Corp.

Read more on URA